<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00488995</url>
  </required_header>
  <id_info>
    <org_study_id>A3671029</org_study_id>
    <nct_id>NCT00488995</nct_id>
  </id_info>
  <brief_title>Safety And Efficacy Study Of CP-675,206 In HIV-Infected Patients</brief_title>
  <official_title>A Phase 2 Study To Evaluate The Safety, Tolerability, Virologic And Immunologic Effect Of Single-Dose CP-675,206 In Patients Infected With Human Immunodeficiency Virus</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Pfizer</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Pfizer</source>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine if CP-675,206, a monoclonal antibody to CTLA4, is
      safe and well-tolerated, reduces viral load, and improves immune function in patients
      infected with HIV.
    </textblock>
  </brief_summary>
  <overall_status>Withdrawn</overall_status>
  <start_date>July 2007</start_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Maximum reduction in HIV plasma RNA between Baseline and Week 12 Maximum increase in CD4+ cell count between Baseline and Week 12</measure>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in CD8+ cell count, CD4/CD8, and lymphocyte phenotype through Week 12</measure>
  </secondary_outcome>
  <enrollment type="Actual">0</enrollment>
  <condition>Human Immunodeficiency Virus</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>CP-675,206</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  HIV infected man or woman at least 18 years of age who is available for a follow up
             period of at least 3 months

          -  Has been on a stable antiretroviral regimen for ≥3 months and willing to remain on
             current antiretroviral regimen for an additional 3 months or has been off of
             antiretroviral therapy for at least 8 weeks and willing to remain off of
             antiretroviral therapy for another 3 months

          -  Plasma HIV 1 RNA ≥5,000 copies/mL measured by Roche Amplicor HIV 1 Monitor at the
             screening visit

          -  CD4 T-cells ≥200 cells/mm3

        Exclusion Criteria:

          -  History of, or significant evidence of risk for, chronic inflammatory or
             autoimmunedisease (eg, Addison's disease, asthma, celiac disease, multiple sclerosis,
             Graves disease, Hashimoto's thyroiditis, inflammatory bowel disease, psoriasis,
             rheumatoid arthritis, systemic lupus erythematosus, etc)

          -  History of inflammatory bowel disease (eg, Crohn's disease or ulcerative colitis),
             celiac disease, or other chronic gastrointestinal conditions associated with diarrhea,
             or current acute colitis of any origin, and any history of diverticulitis (even a
             single episode) or evidence of diverticulitis at baseline, including evidence limited
             to CT-scan only

          -  Exposure within the previous 3 months to a drug known to have immunomodulatory effects
             (eg, IL 2)
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Pfizer CT.gov Call Center</last_name>
    <role>Study Director</role>
    <affiliation>Pfizer</affiliation>
  </overall_official>
  <link>
    <url>https://trialinfoemail.pfizer.com/pages/landing.aspx?StudyID=A3671029&amp;StudyName=Safety+And+Efficacy+Study+Of+CP%2D675%2C206+In+HIV%2DInfected+Patients</url>
    <description>To obtain contact information for a study center near you, click here.</description>
  </link>
  <verification_date>March 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>June 19, 2007</study_first_submitted>
  <study_first_submitted_qc>June 19, 2007</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 20, 2007</study_first_posted>
  <last_update_submitted>March 10, 2015</last_update_submitted>
  <last_update_submitted_qc>March 10, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">March 11, 2015</last_update_posted>
  <responsible_party>
    <name_title>Director, Clinical Trial Disclosure Group</name_title>
    <organization>Pfizer, Inc.</organization>
  </responsible_party>
  <keyword>HIV Therapeutic Vaccine</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Immunologic Deficiency Syndromes</mesh_term>
    <mesh_term>Acquired Immunodeficiency Syndrome</mesh_term>
    <mesh_term>HIV Infections</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Tremelimumab</mesh_term>
    <mesh_term>Antibodies, Monoclonal</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

